Skip to main content
. 2009 Feb 17;100(4):737–746. doi: 10.1111/j.1349-7006.2009.01083.x

Figure 1.

Figure 1

Dehydroxymethylepoxyquinomicin (DHMEQ) inhibited constitutive NF‐κB binding activity in primary effusion lymphoma (PEL) cell lines. (A) Sub‐components of NF‐κB activity in PEL cell lines. Nuclear extracts (1 µg) of cells were subjected to supershift analysis with indicated antibodies. (B) Effect of DHMEQ on NF‐κB binding activity. PEL cell lines (TY1, BCBL1 and BC1) were treated with DHMEQ (10 µg/mL) for indicated hours. Nuclear extracts were examined for NF‐κB binding activity by electrophoretic mobility shift analysis (EMSA) with a radio‐labeled NF‐κB‐specific probe. Lower panels: results of Oct –1 probe as controls.